CAMBRIDGE, MA, Concerto Biosciences, a biotechnology company, announced that it raised $23 million in a Series A funding round.
Concerto Biosciences, a biotechnology company designing microbial communities that restore deficient microbiomes to treat disease, announced that it raised $23 million in a Series A funding round led by Safar Partners and joined by Horizons Ventures and M Ventures among others. Representatives from Safar Partners and M Ventures will join the company's board of directors.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
